Kontafarma China Holdings Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Kontafarma China Holdings te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	10.9%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Oct 09

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Sep 04

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

May 31

There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

May 24

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

Sep 15

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Apr 20

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Nov 04

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

Feb 18

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Dec 07

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Kontafarma China Holdings onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

SEHK:1312 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (HKD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	837	-63	62	80	N/A
3/31/2024	823	-46	38	59	N/A
12/31/2023	809	-29	13	37	N/A
9/30/2023	841	-12	N/A	N/A	N/A
6/30/2023	874	5	-23	21	N/A
3/31/2023	884	-40	-38	9	N/A
12/31/2022	894	-85	-54	-2	N/A
9/30/2022	997	-24	N/A	N/A	N/A
6/30/2022	869	-10	-6	60	N/A
3/31/2022	836	-29	-11	68	N/A
12/31/2021	803	-48	-16	75	N/A
6/30/2021	938	-119	-182	12	N/A
3/31/2021	974	-81	-78	110	N/A
12/31/2020	1,009	-42	26	207	N/A
6/30/2020	661	66	145	228	N/A
3/31/2020	791	60	43	127	N/A
12/31/2019	921	54	-59	26	N/A
9/30/2019	1,280	29	-6	72	N/A
6/30/2019	1,666	22	47	118	N/A
3/31/2019	1,880	27	21	93	N/A
12/31/2018	2,094	32	-5	67	N/A
9/30/2018	1,985	12	-74	7	N/A
6/30/2018	1,876	-8	-143	-53	N/A
3/31/2018	1,610	-5	N/A	-50	N/A
12/31/2017	1,344	-2	N/A	-47	N/A
9/30/2017	1,175	-15	N/A	-68	N/A
6/30/2017	1,006	-27	N/A	-89	N/A
3/31/2017	820	-32	N/A	-38	N/A
12/31/2016	633	-37	N/A	12	N/A
9/30/2016	539	-43	N/A	-16	N/A
6/30/2016	445	-49	N/A	-43	N/A
3/31/2016	456	-41	N/A	-72	N/A
12/31/2015	466	-34	N/A	-100	N/A
9/30/2015	547	-18	N/A	-36	N/A
6/30/2015	628	-2	N/A	28	N/A
3/31/2015	681	8	N/A	10	N/A
12/31/2014	733	17	N/A	-8	N/A
9/30/2014	747	28	N/A	-40	N/A
6/30/2014	761	38	N/A	-72	N/A
3/31/2014	732	35	N/A	-68	N/A
12/31/2013	703	33	N/A	-64	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van 1312 boven de spaarquote ( 2.3% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van 1312 naar verwachting sneller zal groeien dan de markt Hong Kong

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van 1312 naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van 1312 naar verwachting sneller zal groeien dan de markt Hong Kong.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van 1312 naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 1312 naar verwachting over 3 jaar hoog zal zijn

Kontafarma China Holdings Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Kontafarma China Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Kontafarma China Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Tongfang Kontafarma Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Tongfang Kontafarma Holdings Limited Provides Earnings Guidance for the Full Year of Fiscal 2020

Recent updates

Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%

First half 2024 earnings released: EPS: HK$0.001 (vs HK$0.007 in 1H 2023)

Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?

Kontafarma China Holdings Limited Announces Board Changes, with Effect from 1 September 2024

Kontafarma China Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

Kontafarma China Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

New major risk - Share price stability

Kontafarma China Holdings Limited Announces CEO Changes

Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns

There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise

New minor risk - Share price stability

Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024

Full year 2023 earnings released: HK$0.005 loss per share (vs HK$0.015 loss in FY 2022)

Kontafarma China Holdings Limited, Annual General Meeting, Jun 07, 2024

Kontafarma China Holdings Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?

First half 2023 earnings released: EPS: HK$0.007 (vs HK$0.009 loss in 1H 2022)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Kontafarma China Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New major risk - Share price stability

Kontafarma China Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Full year 2022 earnings released: HK$0.015 loss per share (vs HK$0.003 loss in FY 2021)

Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?

Less than half of directors are independent

Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?

First half 2022 earnings released: HK$0.011 loss per share (vs HK$0.014 loss in 1H 2021)

Tongfang Kontafarma Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Tongfang Kontafarma Holdings Limited to Report First Half, 2022 Results on Aug 29, 2022

Less than half of directors are independent

Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?

Tongfang Kontafarma Holdings Limited Announces Management Changes

Full year 2021 earnings released: HK$0.003 loss per share (vs HK$0.008 loss in FY 2020)

Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?

Executive Director Bingzhang Wei has left the company

Less than half of directors are independent

Tongfang Kontafarma Holdings Limited Provides Earnings Guidance for the Full Year of Fiscal 2020

Tongfang Kontafarma Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares

These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively

Minyi Holdings Limited entered into an agreement to acquire Real Jade Limited from Tongfang Kontafarma Holdings Limited (SEHK:1312) for approximately HKD 350 million.

First half earnings released

First half earnings released

Tongfang Kontafarma Holdings Limited to Report First Half, 2020 Results on Aug 28, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven